NCT06627738RecruitingPhase 2
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 3 Oct 2024
- Start date
- 10 Jun 2025
- Primary completion date
- Feb 2034
- Lead sponsor
- Centre Antoine Lacassagne
- Diseases
- Lung cancer
- NCT number
- NCT06627738
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 42
- From 10 Jun 2025 to the primary completion date, Feb 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pulmonary function test contraindicating radiotherapy: PFT-FEV1 inferior to 1 L.
- After radio-chemotherapy, presence of any toxicity contraindicating Cyberknife irradiation
- Vulnerable populations and participants as defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017:
- Incapacitated participants who have not given or refused informed consent prior to the onset of their incapacity, who are not under the provisions of article 64 ;
- Pregnant or breast-feeding women who are not covered by the provisions of article 66 ;
- Adults under legal protection or unable to express their consent.
Other illness
- Exercise-induced dyspnea associated with heart failure equal to or greater than stage III of the New York Heart Association (NYHA) classification, (appendix 3)
- Coronary syndrome or heart failure in the last three months
Lab values
- Positive EGFR mutation
Who the study is looking for
- Patients aged 18 years old or more
- ECOG 0 to 2
- Histologically proven non-small cell lung cancer
- Stage III non-metastatic tumor, not allowing for immediate surgery
- Volume(s) on the evaluation chest CT scan done at the end of conventional radiotherapy (between 34 \& 46 Gy) meeting the following criteria:
- 1 to 3 target volumes of less than 5 cm in greatest diameter
- And allowing for the delivery of a CyberKnife boost to be carried out in compliance with the manufacturer requirements and with the doses delivered to the organs at risk (OAR/fractions) defined in appendix 2
- Patients who have received a " Taxcis " treatment consisting in 2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)
- No contraindication to implantable venous devices (IVDs)
- Patient who has read the patient information note and signed the consent form
- If applicable, negative pregnancy test\*
- Eligible for National Health Insurance in France
- Chest CT scan performed prior to Taxcis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Antoine Lacassagne Coordinator of this site? Confirm its status | Nice | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.